Pharmacists in Vails Gate, NY Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Carson Brady, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 384 Windsor Highway, Vails Gate, NY 12553 Phone: 845-863-1054 |
William C Mannino, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 374 Windsor Hwy, Suite 100, Vails Gate, NY 12584 Phone: 845-561-1320 Fax: 845-561-1986 |
Mr. Anthony Cytryn Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Route 32, 384 Windsor Hwy, Vails Gate, NY 12584 Phone: 845-863-1054 Fax: 845-863-1056 |
 Migdalia Mighty Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 416 Windsor Highway, Vails Gate, NY 12584 Phone: 845-562-4010 |
Michael E. Kolman, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 374 Windsor Hwy, Suite 100, Vails Gate, NY 12584 Phone: 845-561-1320 Fax: 845-561-1986 |
Mr. Leonard Abate Jr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 384 Windsor Highway, Route 32,, Vails Gate, NY 12584 Phone: 845-863-1054 |
News Archive
First Edition: July 22, 2014
Reporting for Kaiser Health News, Susan Jaffe writes: "Medicare officials have allowed patients at dozens of hospitals participating in pilot projects across the country to be exempted from the controversial requirement that limits nursing home coverage to seniors admitted to a hospital for at least three days.
Study: 23% of doctors have negative perceptions on quality, effectiveness of generic drugs
A new study by researchers at Harvard, Brigham and Women's Hospital and CVS Caremark finds that 23 percent of doctors' have negative perceptions of the effectiveness and quality of generic drugs and that may lead to doctors prescribing unnecessarily expensive medications.
Oncotype DX assay linked to decrease in chemotherapy use in younger patients
In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial diagnostic tool, Oncotype DX, was associated with a decrease in chemotherapy use in younger patients, but not in those over 66 years of age.
Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009
Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.
› Verified 6 days ago